Barr Closes Another Chapter In Quest For Generic Premarin
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will withdraw its ANDA for a version of Wyeth’s conjugated estrogen product after an appeals court affirms decision against raw materials supplier. Barr says it “will continue to review all options regarding its efforts to bring a generic version” of Premarin to market.